150301-88-5

Upstream product

• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 103788-59-6 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde 
• 141820-05-5 4-<2-(5-methyl-2-phenyloxazol-4-yl)ethoxy>benzaldehyde oxime 

Downstream Products

• 150321-05-4 1-[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-1-hydroxyurea 
• 150301-90-9 C₂₁H₂₃N₃O₄ 

Relevant academic research and scientific papers

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5- lipoxygenase

Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relationship studies have demonstrated that electronegative substituents on the 2-phenyl portion of the oxazole tail increased the ex vivo potency of these

Hypoglycemic hydroxyurea derivatives

There are disclosed preparative processes and hypoglycemic compounds of the formula STR1 wherein R is hydrogen or C1 to C3 alkyl; R1 and R2 are taken together and are carbonyl; or R1 and R2 are taken separately, wherein R1 is hydrogen or R4 and R2 is--COR5 and COOR5 ; R3, R4 and R5 are each independently C1 to C9 alkyl, C3 to C7 cycloalkyl, phenyl, naphthyl, furyl, benzofuryl or thienyl or one of said groups mono- or disubstituted with C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 alkoxy-carbonyl, trifluoromethyl, fluoro or chloro; and n is 0 or 1; or pharmaceutically acceptable cationic salts thereof.